Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Terry O'Neill Elected New "National Organization for Women" President
The National Organization for Women on Saturday during its annual conference elected Terry O"Neill as the group"s new president, the Indianapolis Star reports. O"Neill succeeds Kim Gandy, who has served two four-year terms as NOW president. The group has grown to include about 500,000 advocate members since its founding in 1966.During the conference, participants discussed a number of women"s rights issues, including same-sex marriage, equal pay and health insurance affordability. O"Neill raised the issue of "conscience" clauses, which allow health care workers to refuse to provide information or services on moral or religious grounds. O"Neill said, "Conscience clauses, where pharmacists refuse birth control sales because it"s against their conscience, must go. Guess what? Women have a constitutional right to birth control," adding, "There is no constitutional right to be a pharmacist" (Jacobs, Indianapolis Star, 6/21).O"Neill served as NOW"s vice president for membership from 2001 to 2005. She most recently served as chief of staff for a county council member in Montgomery County, Md. O"Neill in a prepared statement said that she is "honored and eager" to lead NOW (AP/Google.com, 6/21).
generic viagra online
USC Researchers Uncover Mechanism That Allows Influenza Virus To Evade The BodyÂðs Immune Response
California (USC) have identified a
News of the day
New Mexico Department Of Health Announces Second Hantavirus Case In NM This Year
The New Mexico Department of Health announced today that a 65-year-old man from San Miguel County is hospitalized in critical condition at University of New Mexico Hospital in Albuquerque with the state"s second case of Hantavirus Pulmonary Syndrome this year. The Department of Health confirmed the case of Hantavirus on Wednesday and is conducting an environmental investigation to look for places where the man may have been exposed to the virus.
Sexual Health

Vaxart Begins Animal Testing Of H1N1 Flu Vaccine Candidate

Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). On Saturday, May 23, Vaxart began testing for immune responses in animals, just 25 days after initiating the project. The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing. The company has also begun preparing material suitable for production of human H1N1 vaccine; an initial batch could be produced by August. However, human testing may not begin until fall or later, due to the need for safety testing in animals. "Our oral vaccine could provide an important tool for swine flu pandemic preparation, because of the speed with which it could be delivered to groups such as first-line medical personnel," said Sean Tucker, Ph.D., Vaxart vice president of research. Currently, pandemic flu vaccines are prepared by a slow and inefficient process that requires about six months before the first large amounts of vaccine are available. This process depends on creating an engineered variant of the circulating pandemic influenza strain and growing it in eggs. An advantage of Vaxart"s approach is that it does not require culturing the flu virus in eggs; company scientists make a new vaccine by inserting a small piece of DNA matching the pandemic strain into Vaxart"s pre-constructed vector. Vaxart"s vector grows quickly and reproducibly in cell culture using a standard process. Vaxart vaccines are novel in several ways, including the fact that they can be taken orally (i.e., by swallowing a capsule). In addition, the product is stable enough to be distributed without refrigeration. In an emergency, an approved Vaxart vaccine could be supplied by mail, rather than risking the spread of disease caused by individuals visiting clinics to receive injections. Vaxart"s approach has important advantages over other platform technologies under development. Vaxart has shown that prior exposure to their platform vector does not impact the performance of later vaccinations. The company has previously demonstrated that its avian flu prototype vaccine has the ability to protect animals from lethal exposure to the pandemic strain. "We look forward to continuing our work with government authorities and funding agencies to pursue this very promising vaccine for H1N1 influenza," said Mark Backer, Ph.D., Vaxart CEO. About Vaxart Vaxart is a privately held biotechnology company focused on the development of oral vaccines. Vaxart"s proprietary approach is ideally suited for modular creation of vaccines, enabling the company to reduce development risk. Vaxart intends to apply its platform to develop a first-in-class vaccine for pandemic influenza, as well as creating oral alternatives to current vaccines such as annual influenza and HPV. The company expects to begin clinical testing of its pandemic flu vaccine in 2009. Vaxart, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009